WallStSmart
SGMO

Sangamo Therapeutics Inc

NASDAQ: SGMO · HEALTHCARE · BIOTECHNOLOGY

$0.14
+2.09% today

Updated 2026-06-05

Market cap
$55.93M
P/E ratio
P/S ratio
1.62x
EPS (TTM)
$-0.38
Dividend yield
52W range
$0 – $1
Volume
10.9M

Sangamo Therapeutics Inc (SGMO) Financial statements

SEC filings — annual and quarterly data.

Profit margin
-310.81%
Operating margin
-273.07%
ROE
-2,892.00%
ROA
-94.40%
Debt/equity

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2006$7.88M$-17.86M100.00%-262.89%-226.56%
2007$9.10M$-21.48M100.00%-272.27%-236.10%
2008$16.19M$-24.30M100.00%-156.77%-150.14%
2009$22.19M$-18.59M100.00%-87.45%-83.77%
2010$20.80M$-24.85M100.00%-119.85%-119.46%
2011$10.32M$-35.75M100.00%-347.14%-346.45%
2012$21.66M$-22.26M100.00%-102.51%-102.81%
2013$24.13M$-26.62M-53.23%-110.66%-110.32%
2014$45.87M$-26.42M-23.71%-58.38%-57.59%
2015$39.54M$-40.70M100.00%-118.51%-102.94%
2016$19.39M$-71.66M100.00%-374.23%-369.58%
2017$36.57M$-54.57M100.00%-154.13%-149.23%
2018$84.45M$-68.33M100.00%-91.35%-80.91%
2019$102.43M$-75.82M100.00%-102.69%-74.02%
2020$118.19M$-121.12M100.00%-109.61%-102.48%
2021$110.70M$-178.30M100.00%-165.61%-161.06%
2022$111.30M$-192.28M100.00%-180.85%-172.76%
2023$176.23M$-257.83M100.00%-155.48%-146.30%
2024$57.80M$-97.94M100.00%-179.88%-169.45%
2025$39.55M$-122.93M80.78%-273.07%-310.81%

Frequently asked questions

What is Sangamo Therapeutics Inc's revenue?

Sangamo Therapeutics Inc's trailing twelve-month revenue is $34.56M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is SGMO?

In its most recent fiscal year, SGMO ran a gross margin of 80.78%, an operating margin of -273.07%, and a net margin of -310.81%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does SGMO generate?

SGMO produced $-97.31M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.